- 首页
- PKD (Protein kinase D)
- Cirtuvivint
Cirtuvivint
Cirtuvivint (SM08502) 是一种有效的具有口服活性的 CDC 样激酶 (CLK) 抑制剂，可用于实体瘤的研究。
此产品仅用于科学研究，我们不为任何个人用途提供产品和服务
-
包装价格促销价数量
-
5mg￥3487.002790.00- +
-
10mg￥5175.004140.00- +
-
25mg￥10575.008460.00- +
- 货号: ajcx35756
- CAS: 2143917-62-6
- 别名: SM08502
- 分子式: C24H25N7O
- 分子量: 427.5
- 纯度: ＞98%
- 溶解度: DMSO : 12.5 mg/mL (29.24 mM; ultrasonic and warming and heat to 60°C)
- 储存: 4°C, away from moisture and light
- 库存: 现货
Background
Cirtuvivint (SM08502) is a potent and orally active CDC-like kinase (CLK) inhibitor. Cirtuvivint can be used for solid tumors research[1].
Cirtuvivint (SM08502) inhibits serine and arginine rich splicing factor (SRSF) phosphorylation and disrupted spliceosome activity, which is associated with inhibition of Wnt pathway-related gene and protein expression. Cirtuvivint induces the generation of splicing variants of Wnt pathway genes, suggesting that its mechanism for inhibition of gene expression includes effects on alternative splicing[1].
Orally administered Cirtuvivint (SM08502) significantly inhibits growth of gastrointestinal tumors and decreased SRSF phosphorylation and Wnt pathway gene expression in xenograft mouse models[1].
[1]. Betty Y Tam, et al. The CLK inhibitor SM08502 induces anti-tumor activity and reduces Wnt pathway gene expression in gastrointestinal cancer models. Cancer Lett. 2020 Mar 31;473:186-197.
